ASA Biopharm's Podcast

Bo Huang and Gene Pennello discuss the 2021 Regulatory-Industry Statistics Workshop.

Joseph Cappelleri and Daniel O’Connor discuss the benefits and challenges in using patient reported outcomes and how to appropriately define clinically-meaningful change.

Haoda Fu, Mengling Liu, Jie Tang, Tian Zheng, and Kelly Zou discuss leadership and the impact of COVID-19 on the workplace.

Karl Peace was chair of the Biopharmaceutical Section in 1990. He discusses his career in the industry, the Jiann-Ping Hsu College of Public Health, and the Biopharmaceutical Applied Statistics Sympo…

Katherine Monti was chair of the Biopharmaceutical Section in 2010. She discusses her career in the industry and how the Section has changed over time. 

Scott Evans, Stephanie Omokaro, Janet Wittes, and Zhiheng Xu discuss the importance of storytelling for the modern statistician. 

Meg Gamalo and Jingjing Ye talk about pediatric drug development and discuss why forming a scientific working group was so important.

Weili talks about publishing, leadership, and her hopes and plans for the Biopharmaceutical Section in 2021.

David shares some of his experiences as the first statistician ever hired at Pfizer.

Kerry Go and Elaine Hoffman discuss vaccine development.

Olga and Natallia discuss their new book Quantitative Methods in Pharmaceutical Research and Development: Concepts and Applications. 

This episode features discussions with 3 mentor-mentee pairs from the Biopharmaceutical Section mentoring program. Conversations include Qing Li and Abie Ekangaki (start 1:25), Samson Ghebremariam an…

Yabing Mai and Thomas Birkner discuss the 2020 Workshop and the changes necessary to go virtual.

Nusrat discusses biomarker analysis throughout clinical development and her recent book Biomarker Analysis in Clinical Trials with R.

Dottie Brown, Ciprian Crainiceanu, and Jean Recta discuss how pain is quantified in human and animal trials.

Nancy Flournoy, Dan Holder, and Jim Rosenberger discuss the mission and history of the National Institute of Statistical Sciences and how it will adapt for the future.

Mouna Akacha, Yongming Qu, and Aileen Ward discuss COVID-19 and the operational and statistical effects on clinical trials.

Meijuan Li discusses precision medicine, diagnostic devices, and the importance of parallel development of drugs and diagnostics. 

Bruce discusses the Japanese regulatory environment, challenges for statistics departments spread across the globe, and his hopes and plans for the Biopharmaceutical Section in 2020.